chloroquine has been researched along with tilorone in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (28.57) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Denny, WA; Feigon, J; Kearns, DR; Leupin, W | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Atzpodien, EA; Csato, M; Doessegger, L; Fischer, H; Lenz, B; Schmitt, G; Singer, T | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Byun, SY; Choi, I; Jeon, S; Kim, S; Ko, M; Lee, J; Park, S; Shum, D | 1 |
| Anderson, SN; Kacew, S; Ruben, Z | 1 |
| Shall, S; Tavassoli, M; Tavassoli, MH | 1 |
| DiPasquale, G; Hubbs, SJ; Marks, RL; Pasternak, RD | 1 |
| D'Amico, DJ; Kenyon, KR | 1 |
| Lüllmann-Rauch, R; Pods, R; Von Witzendorff, B | 2 |
| Bodem, J; Diesendorf, V; Fähr, S; Geiger, N; Obernolte, H; Roll, V; Sewald, K | 1 |
14 other study(ies) available for chloroquine and tilorone
| Article | Year |
|---|---|
Interactions of antitumor drugs with natural DNA: 1H NMR study of binding mode and kinetics.
Topics: Antineoplastic Agents; Base Composition; Chemical Phenomena; Chemistry; DNA; Hydrogen Bonding; Intercalating Agents; Kinetics; Magnetic Resonance Spectroscopy; Structure-Activity Relationship | 1984 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Topics: Animals; Cattle; Cells, Cultured; Computer Simulation; Cornea; Drug-Related Side Effects and Adverse Reactions; Fibroblasts; Lipidoses; Lysosomal Storage Diseases; Models, Molecular; Pharmaceutical Preparations; Phospholipids; Structure-Activity Relationship; Thermodynamics | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Niclosamide; Pandemics; Pneumonia, Viral; Pregnenediones; SARS-CoV-2; Vero Cells | 2020 |
Changes in saccharide and phospholipid content associated with drug storage in cultured rabbit aorta muscle cells.
Topics: Amines; Amiodarone; Animals; Anti-Arrhythmia Agents; Aorta; Cells, Cultured; Chloroquine; Desipramine; Ethylenediamines; Kinetics; Microscopy, Electron; Monosaccharides; Muscle, Smooth, Vascular; Phospholipids; Piperidines; Rabbits; Tilorone | 1991 |
Effect of DNA intercalators on poly(ADP-ribose) glycohydrolase activity.
Topics: Aminoacridines; Amsacrine; Animals; Chloroquine; Daunorubicin; DNA; Ellipticines; Ethacridine; Ethidium; Glycoside Hydrolases; Histones; Intercalating Agents; Kinetics; Proflavine; Swine; Thymus Gland; Tilorone | 1985 |
Effect of antirheumatic agents on the mitogen response of arthritic rat spleen cells.
Topics: Animals; Anti-Inflammatory Agents; Arthritis; Arthritis, Experimental; Arthritis, Rheumatoid; Chloroquine; Gold Sodium Thiomalate; Levamisole; Lymphocyte Activation; Male; Penicillamine; Rats; Rats, Inbred Lew; Spleen; Tilorone | 1985 |
Drug-induced lipidoses of the cornea and conjunctiva.
Topics: Amiodarone; Amodiaquine; Chloroquine; Conjunctival Diseases; Corneal Diseases; Fabry Disease; Female; Gentamicins; Humans; Hydroquinones; Lipidoses; Male; Tilorone | 1981 |
Tilorone-induced lysosomal storage of sulphated glycosaminoglycans can be separated from tilorone-induced enhancement of lysosomal enzyme secretion.
Topics: Ammonium Chloride; Animals; beta-N-Acetylhexosaminidases; Cattle; Cells, Cultured; Chloroquine; Dose-Response Relationship, Drug; Fibroblasts; Glycosaminoglycans; Lysosomes; Mucopolysaccharidoses; Tilorone | 1995 |
The antimalarials quinacrine and chloroquine induce weak lysosomal storage of sulphated glycosaminoglycans in cell culture and in vivo.
Topics: Animals; Anti-Inflammatory Agents; Antimalarials; beta-N-Acetylhexosaminidases; Cattle; Cells, Cultured; Chloroquine; Dose-Response Relationship, Drug; Female; Fibroblasts; Glycosaminoglycans; Histocytochemistry; Lipidoses; Liver; Lysosomes; Microscopy, Electron; Microscopy, Fluorescence; Mucopolysaccharidoses; Quinacrine; Rats; Rats, Wistar; Structure-Activity Relationship; Sulfates; Tilorone | 1996 |
Drug-induced phospholipidosis is not correlated with the inhibition of SARS-CoV-2 - inhibition of SARS-CoV-2 is cell line-specific.
Topics: Antiviral Agents; Cell Line; Chloroquine; COVID-19; Fluoxetine; Humans; SARS-CoV-2; Tilorone | 2023 |